TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04626674: A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Amb

Sponsor: Sarepta Therapeutics, Inc. · Phase: PHASE1 · Area: RARE_ORPHAN · Target Enrollment: 83 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$420,240

Rescue Site Savings

+$280,160

Unlock Full NCT04626674 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04626674 Rescue Dossier →